Latest News

Feb 26, 2013 BV 4 Portfolio Company Chiasma and Roche Announce Collaboration to Develop and Commercialize Chiasma’s Octreolin® for Acromegaly and Neuroendocrine Tumors

Nov 28, 2012 BV 5 Portfolio Company Rhythm Expands Series B Financing to $33 Million; Adds Pfizer Ventures as an Investor

Nov 07, 2012 BV 4 and BV 5 Portfolio Company Astute Medical, Inc. named by WSJ as Top 10 Venture-Backed Health-Care Company

Nov 07, 2012 BV 3 Portfolio Company Portola Pharmaceuticals named as Top Ten Venture-Backed Health-Care Company

Oct 01, 2012 BV 4 Portfolio Company Epizyme Publishes Landmark Data on Personalized Therapeutics for Lymphomas